NasdaqCM:ONCT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Oncternal Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ONCT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 38% a week.

Volatility Over Time: ONCT's weekly volatility has increased from 21% to 38% over the past year.


Market Performance


7 Day Return

13.6%

ONCT

4.5%

US Biotechs

0.6%

US Market


1 Year Return

-43.4%

ONCT

26.3%

US Biotechs

22.7%

US Market

Return vs Industry: ONCT underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: ONCT underperformed the US Market which returned 21% over the past year.


Shareholder returns

ONCTIndustryMarket
7 Day13.6%4.5%0.6%
30 Day88.4%14.1%13.1%
90 Day37.7%10.5%4.5%
1 Year-43.4%-43.4%28.4%26.3%25.5%22.7%
3 Yearn/a27.3%20.7%49.0%39.1%
5 Yearn/a15.3%7.4%98.3%76.5%

Long-Term Price Volatility Vs. Market

How volatile is Oncternal Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncternal Therapeutics undervalued compared to its fair value and its price relative to the market?

4.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ONCT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ONCT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ONCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ONCT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ONCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ONCT is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Oncternal Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

4.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ONCT's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if ONCT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ONCT's revenue (4.2% per year) is forecast to grow slower than the US market (10.3% per year).

High Growth Revenue: ONCT's revenue (4.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ONCT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oncternal Therapeutics performed over the past 5 years?

39.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ONCT is currently unprofitable.

Growing Profit Margin: ONCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ONCT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ONCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: ONCT has a negative Return on Equity (-119.9%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oncternal Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ONCT's short term assets ($22.7M) exceed its short term liabilities ($7.6M).

Long Term Liabilities: ONCT's short term assets ($22.7M) exceed its long term liabilities ($301.0K).


Debt to Equity History and Analysis

Debt Level: ONCT's debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ONCT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ONCT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 29.6% each year.


Next Steps

Dividend

What is Oncternal Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ONCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jim Breitmeyer (66 yo)

no data

Tenure

US$1,115,838

Compensation

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph.D., serves as Director of Otonomy, Inc. since June 20, 2018. He serves as the Chief Executive Officer and President of Oncternal Therapeutics, Inc. Dr. ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.12M) is above average for companies of similar size in the US market ($USD561.31K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James Breitmeyer
Presidentno dataUS$1.12m0.94%
$ 813.5k
Frank Hsu
Chief Medical Officer1.25yrsUS$1.33m0%
$ 0
Richard Vincent
CFO, Treasurer & Secretary3.5yrsno data0.16%
$ 137.7k
Gunnar Kaufmann
Chief Scientific Officer1.17yrsno datano data
Rajesh Krishnan
Senior Vice President of Chemistry1.25yrsno datano data
Igor Bilinsky
Chief Business Officer1.17yrsno datano data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Management: ONCT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
James Breitmeyer
Presidentno dataUS$1.12m0.94%
$ 813.5k
Michael Carter
Independent Director1.83yrsUS$146.03k0.24%
$ 210.1k
Daniel Kisner
Independent Director1.83yrsUS$148.58k0.034%
$ 29.2k
William LaRue
Independent Director1.83yrsUS$148.30k0.055%
$ 48.0k
David Hale
Independent Chairman1.83yrsUS$272.80k0%
$ 0
Thomas Kipps
Scientific Advisorno datano datano data
Charles Theuer
Independent Director2.5yrsUS$143.77k0.050%
$ 42.9k
Man Cho
Independent Director0.92yrUS$89.71k0%
$ 0
Robert Wills
Non-Independent Director1.42yrsUS$484.31k0%
$ 0
Jeffrey Toretsky
Scientific Advisorno datano datano data
Xin Nakanishi
Independent Director2.83yrsUS$141.50k0%
$ 0

1.8yrs

Average Tenure

66yo

Average Age

Experienced Board: ONCT's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 92.4%.


Top Shareholders

Company Information

Oncternal Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncternal Therapeutics, Inc.
  • Ticker: ONCT
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$86.446m
  • Shares outstanding: 29.60m
  • Website: https://www.oncternal.com

Number of Employees


Location

  • Oncternal Therapeutics, Inc.
  • 12230 El Camino Real
  • Suite 300
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2019
GTU2DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2019

Biography

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company’s product pipeline include c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 23:25
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.